Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.

Hirt UA, Waizenegger IC, Schweifer N, Haslinger C, Gerlach D, Braunger J, Weyer-Czernilofsky U, Stadtmüller H, Sapountzis I, Bader G, Zoephel A, Bister B, Baum A, Quant J, Kraut N, Garin-Chesa P, Adolf GR.

Oncogenesis. 2018 Feb 23;7(2):21. doi: 10.1038/s41389-018-0032-z.

2.

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

Hilberg F, Tontsch-Grunt U, Baum A, Le AT, Doebele RC, Lieb S, Gianni D, Voss T, Garin-Chesa P, Haslinger C, Kraut N.

J Pharmacol Exp Ther. 2018 Mar;364(3):494-503. doi: 10.1124/jpet.117.244129. Epub 2017 Dec 20.

PMID:
29263244
3.

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.

Sanderson MP, Hofmann MH, Garin-Chesa P, Schweifer N, Wernitznig A, Fischer S, Jeschko A, Meyer R, Moll J, Pecina T, Arnhof H, Weyer-Czernilofsky U, Zahn SK, Adolf GR, Kraut N.

Mol Cancer Ther. 2017 Oct;16(10):2223-2233. doi: 10.1158/1535-7163.MCT-17-0336. Epub 2017 Jul 20.

PMID:
28729397
4.

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML.

Nat Commun. 2017 Feb 10;8:14262. doi: 10.1038/ncomms14262.

5.

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.

Sini P, Gürtler U, Zahn SK, Baumann C, Rudolph D, Baumgartinger R, Strauss E, Haslinger C, Tontsch-Grunt U, Waizenegger IC, Solca F, Bader G, Zoephel A, Treu M, Reiser U, Garin-Chesa P, Boehmelt G, Kraut N, Quant J, Adolf GR.

Mol Cancer Ther. 2016 Oct;15(10):2388-2398. Epub 2016 Aug 5.

6.

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.

Waizenegger IC, Baum A, Steurer S, Stadtmüller H, Bader G, Schaaf O, Garin-Chesa P, Schlattl A, Schweifer N, Haslinger C, Colbatzky F, Mousa S, Kalkuhl A, Kraut N, Adolf GR.

Mol Cancer Ther. 2016 Mar;15(3):354-65. doi: 10.1158/1535-7163.MCT-15-0617. Epub 2016 Feb 25.

7.

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.

Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F.

J Clin Oncol. 2016 Mar 1;34(7):706-13. doi: 10.1200/JCO.2015.62.1474. Epub 2016 Jan 11.

PMID:
26755507
8.

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.

Sanderson MP, Apgar J, Garin-Chesa P, Hofmann MH, Kessler D, Quant J, Savchenko A, Schaaf O, Treu M, Tye H, Zahn SK, Zoephel A, Haaksma E, Adolf GR, Kraut N.

Mol Cancer Ther. 2015 Dec;14(12):2762-72. doi: 10.1158/1535-7163.MCT-15-0539. Epub 2015 Oct 5.

9.

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.

Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, Tontsch-Grunt U, Wernitznig A, Savarese F, Hofmann MH, Albrecht C, Geiselmann L, Reschke M, Garin-Chesa P, Zuber J, Moll J, Adolf GR, Kraut N.

J Pharmacol Exp Ther. 2015 Mar;352(3):579-89. doi: 10.1124/jpet.114.221150. Epub 2015 Jan 9.

10.

IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction.

Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, Artaker M, Nivarthi H, Moriggl R, Hengstschläger M, Kerjaschki D, Sommergruber W, Dolznig H, Garin-Chesa P.

Oncogene. 2015 Feb 12;34(7):815-25. doi: 10.1038/onc.2014.18. Epub 2014 Mar 17.

PMID:
24632618
11.

A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.

Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H.

Br J Haematol. 2013 Oct;163(2):214-22. doi: 10.1111/bjh.12518. Epub 2013 Aug 16.

PMID:
24033250
12.

Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction.

Dolznig H, Rupp C, Puri C, Haslinger C, Schweifer N, Wieser E, Kerjaschki D, Garin-Chesa P.

Am J Pathol. 2011 Jul;179(1):487-501. doi: 10.1016/j.ajpath.2011.03.015. Epub 2011 Apr 30.

13.

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR.

Clin Cancer Res. 2009 May 1;15(9):3094-102. doi: 10.1158/1078-0432.CCR-08-2445. Epub 2009 Apr 21.

14.

Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.

Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR.

Clin Cancer Res. 2008 Jul 15;14(14):4584-92. doi: 10.1158/1078-0432.CCR-07-5211.

15.

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ.

Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.

16.

hGPR87 contributes to viability of human tumor cells.

Glatt S, Halbauer D, Heindl S, Wernitznig A, Kozina D, Su KC, Puri C, Garin-Chesa P, Sommergruber W.

Int J Cancer. 2008 May 1;122(9):2008-16. doi: 10.1002/ijc.23349.

17.

Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma.

Koperek O, Scheuba C, Puri C, Birner P, Haslinger C, Rettig W, Niederle B, Kaserer K, Garin Chesa P.

Int J Oncol. 2007 Jul;31(1):59-67.

PMID:
17549405
18.

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.

Curr Biol. 2007 Feb 20;17(4):316-22. Epub 2007 Feb 8.

19.

Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis.

Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P.

Cancer Immun. 2006 Jul 31;6:10.

20.

Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin.

Rupp C, Dolznig H, Puri C, Schweifer N, Sommergruber W, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P.

Diagn Mol Pathol. 2006 Mar;15(1):35-42.

PMID:
16531767
21.

Expression of stromal cell markers in distinct compartments of human skin cancers.

Huber MA, Kraut N, Schweifer N, Dolznig H, Peter RU, Schubert RD, Scharffetter-Kochanek K, Pehamberger H, Garin-Chesa P.

J Cutan Pathol. 2006 Feb;33(2):145-55.

PMID:
16420310
22.

Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.

Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P.

Cancer Immun. 2005 Aug 3;5:10.

23.

FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor.

Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN.

Oncogene. 2004 Jul 15;23(32):5435-46.

PMID:
15133496
24.

Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.

Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, Obata Y, Stockert E, Hall CM, Old LJ, Rettig WJ, Scott AM.

Mol Cancer Ther. 2003 Aug;2(8):729-37.

25.

Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.

Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, Garin-Chesa P.

J Invest Dermatol. 2003 Feb;120(2):182-8.

26.

Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate.

Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A.

J Biol Chem. 2002 May 3;277(18):15566-72. Epub 2002 Feb 19.

27.

A highly selective telomerase inhibitor limiting human cancer cell proliferation.

Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, Lauritsch I, Müller E, Pascolo E, Sauter G, Pantic M, Martens UM, Wenz C, Lingner J, Kraut N, Rettig WJ, Schnapp A.

EMBO J. 2001 Dec 17;20(24):6958-68.

28.

Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.

Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, Moosmayer D.

Mol Med. 2001 Jul;7(7):461-9.

29.

Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium.

Christian S, Ahorn H, Novatchkova M, Garin-Chesa P, Park JE, Weber G, Eisenhaber F, Rettig WJ, Lenter MC.

J Biol Chem. 2001 Dec 21;276(51):48588-95. Epub 2001 Sep 14.

30.

Expression of the fibroblast activation protein during mouse embryo development.

Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, Bamberger U, Rettig WJ, Schnapp A.

Int J Dev Biol. 2001 Apr;45(2):445-7.

31.

Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.

Mersmann M, Schmidt A, Rippmann JF, Wüest T, Brocks B, Rettig WJ, Garin-Chesa P, Pfizenmaier K, Moosmayer D.

Int J Cancer. 2001 Apr 15;92(2):240-8.

32.

Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.

Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, Finn RD, Larson SM, Old LJ, Scott AM.

Br J Clin Pharmacol. 2001 Feb;51(2):177-80.

33.

Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.

Schmidt A, Müller D, Mersmann M, Wüest T, Gerlach E, Garin-Chesa P, Rettig WJ, Pfizenmaier K, Moosmayer D.

Eur J Biochem. 2001 Mar;268(6):1730-8.

34.

Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium.

Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, Park JE, Rettig WJ, Lenter MC.

J Biol Chem. 2001 Mar 9;276(10):7408-14. Epub 2000 Nov 17.

35.

Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis.

Rippmann JF, Hobbie S, Daiber C, Guilliard B, Bauer M, Birk J, Nar H, Garin-Chesa P, Rettig WJ, Schnapp A.

Cell Growth Differ. 2000 Jul;11(7):409-16.

36.

Targeted disruption of mouse fibroblast activation protein.

Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ, Schnapp A.

Mol Cell Biol. 2000 Feb;20(3):1089-94.

37.

Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.

Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ.

J Biol Chem. 1999 Dec 17;274(51):36505-12.

38.

In vitro detection of occult bone marrow metastases in patients with colorectal cancer hepatic metastases.

Cohen AM, Garin-Chesa P, Hanson M, Weyhrauch K, Kemeny N, Fong Y, Paty P, Welt S, Old L.

Dis Colon Rectum. 1998 Sep;41(9):1112-5.

PMID:
9749494
39.

p53 mutations in chondrosarcoma.

Terek RM, Healey JH, Garin-Chesa P, Mak S, Huvos A, Albino AP.

Diagn Mol Pathol. 1998 Feb;7(1):51-6.

PMID:
9646035
40.

Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers.

Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A.

Int J Cancer. 1997 May 2;71(3):383-9.

41.

Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years.

Lieberman PH, Jones CR, Steinman RM, Erlandson RA, Smith J, Gee T, Huvos A, Garin-Chesa P, Filippa DA, Urmacher C, Gangi MD, Sperber M.

Am J Surg Pathol. 1996 May;20(5):519-52.

PMID:
8619419
42.

TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.

Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P.

J Urol. 1995 May;153(5):1575-9.

PMID:
7536270
43.

The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23.

Mathew S, Scanlan MJ, Mohan Raj BK, Murty VV, Garin-Chesa P, Old LJ, Rettig WJ, Chaganti RS.

Genomics. 1995 Jan 1;25(1):335-7. No abstract available.

PMID:
7774951
44.

Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants.

Kitamura K, Stockert E, Garin-Chesa P, Welt S, Lloyd KO, Armour KL, Wallace TP, Harris WJ, Carr FJ, Old LJ.

Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12957-61.

45.

Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin superfamily.

Campbell IG, Foulkes WD, Senger G, Trowsdale J, Garin-Chesa P, Rettig WJ.

Cancer Res. 1994 Nov 15;54(22):5761-5.

46.

TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines.

Xu L, Davidson BJ, Murty VV, Li RG, Sacks PG, Garin-Chesa P, Schantz SP, Chaganti RS.

Int J Cancer. 1994 Nov 1;59(3):383-7.

PMID:
7927946
47.

Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels.

Sanz-Moncasi MP, Garin-Chesa P, Stockert E, Jaffe EA, Old LJ, Rettig WJ.

Lab Invest. 1994 Sep;71(3):366-73.

PMID:
7933987
48.

Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.

Yoshikawa H, Rettig WJ, Lane JM, Takaoka K, Alderman E, Rup B, Rosen V, Healey JH, Huvos AG, Garin-Chesa P.

Cancer. 1994 Aug 1;74(3):842-7.

PMID:
8039112
49.

Fibroblast activation protein: purification, epitope mapping and induction by growth factors.

Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, Healey JH, Old LJ.

Int J Cancer. 1994 Aug 1;58(3):385-92.

PMID:
7519584
50.

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.

Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61.

Supplemental Content

Loading ...
Support Center